Wouter Meuleman, Ph.D.


Wouter Meuleman, Ph.D.


Wouter was part of the founding team at Illumina Ventures, and brings 15+ years of experience in life science tools development and genomics to the fund.

Prior to Illumina Ventures, he was Director of Corporate Development at Illumina Inc., where he led investments including Desktop Genetics (acquired by Celixir in 2018). During his time at Illumina Inc., Wouter also held roles in R&D and Product Development, where he was instrumental in the development of sequencing platforms, the sourcing and evaluation of new technology opportunities, and competitive benchmarking.

An electrochemist by training, Wouter made his debut in life sciences in 2003 as first hire for Oxford University spin-out Oxamer, a company founded by Lasker-award winner Professor Sir Edwin Southern, where he contributed to the development of a benchtop DNA microarray fabrication platform. Following the company’s merger with Oxford Gene Technology (later acquired by Sysmex), he continued working alongside Prof. Southern, leading R&D on single cell gene expression analysis and novel applications for DNA microarrays.

Wouter obtained a joint B.Sc./M.Sc. (magna cum laude) in Chemistry from the University of Ghent, Belgium, a Ph.D. in Chemical Engineering from the University of Newcastle, U.K., and an M.B.A. from the University of Cambridge, U.K.

Portfolio Involvement

  • Arbor Biotechnologies
  • Delfi Diagnostics
  • Fluent Biosciences
  • RedShiftBio
  • Ribometrix
  • Sherlock Biosciences
View Full Team